TetraLogic Pharmaceuticals has an experienced management team with complementary expertise in research and development, clinical development, commercialization, finance and operations management. Together, the team has significant leadership capabilities for building a successful biopharmaceutical company.
Mr. Buchi was most recently Corporate Vice President, Global Branded Products, at Teva Pharmaceutical Industries Ltd. Prior to joining Teva, he was Chief Executive Officer of Cephalon, Inc., which was acquired by Teva for $8 billion in October 2011. Mr. Buchi joined Cephalon in 1991 and held various positions, including Chief Financial Officer and Chief Operating Officer, before becoming Cephalon’s Chief Executive Officer in December 2010. He graduated from Cornell University with a Bachelor of Arts degree in chemistry and received a Master of Management degree from the J.L. Kellogg Graduate School of Management at Northwestern University. Mr. Buchi is a Certified Public Accountant.
Mr. Sherman joined TetraLogic Pharmaceuticals in 2012 and previously provided consulting services to TetraLogic as Vice President, Strategic Partnering and Transactions at Malvern Consulting Group. He spent more than a decade (1976-1989) as Deputy General Counsel of SmithKline Beckman Corporation (now GlaxoSmithKline), was a partner in the law firm of Pepper Hamilton LLP (1990-1992), and was founder and managing officer (1992-2001) of QED Technologies, Inc., a life science business consulting firm purchased in 1999 by The Omnicom Group in New York. He is a principal in a private SBIC Investment fund, CIP Capital, L.P. and a venture partner in the SCP/Vitalife family of funds in suburban Philadelphia. Mr. Sherman has served on the Board of Directors of a number of for-profit companies, including Biophage, Inc., CytoMed, Inc., IBAH, Inc., Kenna Technologies, Inc., Mera Pharmaceuticals, Inc., and Sparta Pharmaceuticals. He is currently a member of the Board of Directors of Functional Technologies Corp., a Vancouver based publicly traded company, Hawaii Biotech, Inc. and Leversense LLC. Mr. Sherman graduated magna cum laude from the University of Nebraska (1968), where he was elected to Phi Beta Kappa. As a Root-Tilden Scholar at the New York University School of Law, he received his Juris Doctor in 1971.
Dr. Condon joined TetraLogic Pharmaceuticals in 2004 as Director of Chemistry and advanced to Vice President of Research before becoming Chief Scientific Officer. Prior to 2004, Dr. Condon was a Group Leader in medicinal chemistry at ViroPharma Corporation where his team prepared and profiled novel inhibitors of the hepatitis C virus NS5B RNA-dependent RNA polymerase including HCV-371 which, in collaboration with Wyeth Pharmaceuticals, was selected for clinical development. From 1995-2000, Dr. Condon was a member of the medicinal chemistry section of Rhône-Poulenc Rorer where his work led to elucidation of the bioactive conformation of human parathyroid hormone (PTH1-34) and the discovery of RPR132561, an anabolic agent for the treatment of post-menopausal osteoporosis. Dr. Condon is an author of over 30 peer-reviewed publications and an inventor on 21 issued US patents. Dr. Condon received his doctoral degree with Professor Amos B. Smith, III at the University of Pennsylvania after completing the total syntheses of rapamycin and demethoxyrapamycin.
Mr. Hutchison joined TetraLogic Pharmaceuticals in February 2014 as Vice President of Finance, advancing to Chief Financial Officer in early 2016. Prior to TetraLogic Pharmaceuticals, Mr. Hutchison was Vice President-Corporate Controller and Chief Accounting Officer at Teleflex, Inc., an international medical device company, in 2012 and 2013. Prior to that, he held the position of Vice President-Group Controller of Cephalon, Inc., for 11 years, until shortly after Cephalon’s acquisition by Teva Pharmaceutical Industries Ltd. in October 2011. Mr. Hutchison was involved in almost all areas of finance at Cephalon during this period, including accounting, financial reporting, budgeting and forecasting, M&A, convertible debt and equity financings, product acquisitions, and collaborations. He began his career on the audit staff of Deloitte in Philadelphia, PA. Mr. Hutchison graduated from the University of Pennsylvania with a Bachelor of Science in Economics from the Wharton School and is an active Certified Public Accountant.
Dr. Meehan joined TetraLogic Pharmaceuticals in 2012 as Vice President of Alliance Management and Operations and has held several positions of increasing responsibility before advancing to Chief Operating Officer. He has more than 20 years of experience in the pharmaceutical and biotechnology industry, working with both large and small start-up firms including Merck, Janssen, and TransForm Pharmaceuticals, in leadership roles across business development, corporate venture, product development, and manufacturing. Over his career, Dr. Meehan has contributed to the development of over 50 investigational molecules and 8 new product registrations. Dr. Meehan holds an M.B.A from the Wharton School of the University of Pennsylvania, a Ph.D. in Chemical Engineering from Carnegie Mellon University and a B.S.E in Chemical Engineering from the University of Pennsylvania.
Dr. Skolnik joined TetraLogic Pharmaceuticals in November 2014 as Vice President of Clinical Research and was recently appointed to Chief Medical Officer. Dr. Skolnik was a US Medical Affairs lead for GSK, and from 2008-2013 was the clinical lead physician for several pivotal oncology programs at AstraZeneca. Dr. Skolnik is a pediatric hematologist-oncologist with experience in both large pharmaceutical and small biotechnology companies. Dr. Skolnik has experience with both early and late-stage clinical development and extensive experience in developing oncology drug programs for children. Dr. Skolnik received his MD degree from the New York University, and has several peer-reviewed publications, one of which serves as the basis for novel trial design methodology in the pediatric oncology space.